[Use of cyclosporin A eyedrops in the prevention of corneal graft rejection in man. I. Preoperative development of 4 eyes with metaherpetic keratitis].
Topical cyclosporine A (2%) has been used to prevent corneal graft rejection in high risk patients. The treatment was begun 48 h at least before surgery. 3 patients (4 eyes) suffering from metaherpetic keratitis were placed under this treatment for a long time due to the delay to obtain a corneal donor. Their observation while treated showed a remarkable slow-down of the inflammation both in conjunctivae and corneas. This confirms if necessary the role of T lymphocytes in metaherpetic corneal diseases and the clinical modulation effect of cyclosporine A on these T cells.
Goichot-Bonnat
L
L
De Beauregard
C
C
Saragoussi
J J
JJ
Pouliquen
Y
Y
D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003319:Corneal Stroma / Q000187:drug effects; D016039:Corneal Transplantation; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007635:Keratitis, Dendritic / Q000503:physiopathology / Q000628:therapy; D008297:Male; D009883:Ophthalmic Solutions; D011292:Premedication; D012008:Recurrence; D012306:Risk; D013601:T-Lymphocytes / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D003524:Cyclosporins; D009883:Ophthalmic Solutions
Usage de la cyclosporine A collyre dans la prévention du rejet de greffe de cornée chez l'homme. I. Evolution préopératoire de 4 yeux atteints de kératite métaherpétique.